Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 20, 1999
Grant Date -
N/A
app pub date -
Jul 21, 1995
filing date -
Jul 21, 1995
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This invention relates to compositions and methods comprising 'lymphotoxin-.beta. receptor blocking agents', which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully